Lytix Biopharma AS (FRA:6BG)

Germany flag Germany · Delayed Price · Currency is EUR
0.850
-0.038 (-4.28%)
Last updated: Dec 5, 2025, 8:03 AM CET
24.27%
Market Cap 59.18M
Revenue (ttm) 32.17K
Net Income (ttm) -6.25M
Shares Out n/a
EPS (ttm) -0.09
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume n/a
Open 0.850
Previous Close 0.888
Day's Range 0.850 - 0.850
52-Week Range 0.372 - 0.934
Beta n/a
RSI 61.86
Earnings Date Nov 18, 2025

About Lytix Biopharma AS

Lytix Biopharma AS, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in the United States. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, which is in Phase II clinical trials, to treat melanoma, basal cell carcinoma, and advanced soft tissue sarcoma. The company also offers LTX-401, an oncolytic molecule in preclinical phase for the treatment of deep-seated tumors, such as hepatocellular carcinoma in liver cancer and liver metastases. It has a... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2003
Employees 8
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 6BG
Full Company Profile

Financial Performance

In 2024, Lytix Biopharma AS's revenue was 11.13 million, an increase of 178.98% compared to the previous year's 3.99 million. Losses were -94.27 million, 7.24% more than in 2023.

Financial numbers in NOK Financial Statements

News

There is no news available yet.